Neurology - PowerPoint PPT Presentation

About This Presentation
Title:

Neurology

Description:

Neurology References Physician s Desk Reference (PDR) White pages manufacturer index of products Pink pages product names by trade name Blue pages products by ... – PowerPoint PPT presentation

Number of Views:127
Avg rating:3.0/5.0
Slides: 63
Provided by: MichaelT48
Category:

less

Transcript and Presenter's Notes

Title: Neurology


1
Neurology
NAPLEX
2
Drugs used for Convulsive Disorders
NAPLEX
PG 88
3
  • The medication lorazepam (Ativan) has which
    of the following pharmacological activities?
  • a. sedative/hypnotic
  • b. anticonvulsant
  • c. muscle relaxant
  • d. anxiolytic
  • e. all of the above

4
  • The medication lorazepam (Ativan) has which
    of the following pharmacological activities?
  • a. sedative/hypnotic
  • b. anticonvulsant
  • c. muscle relaxant
  • d. anxiolytic
  • e. all of the above

5
Major Types of Convulsive Disorders
  • Partial generally involves only one
    hemisphere of the brain (initially) and
    asymmetrical
  • Simple-no loss of consciousness
  • Complex-loss of consciousness
  • Phenytoin, carbamazepine, barbiturates,
    valproate
  • Generalized generally involves both
    hemispheres of the brain bilateral/symmetrical
  • absence, myoclonic, clonic, tonic, tonic-clonic,
  • Valproate, lamotrigine, carbamazepine,
    ethosuximide
  • Status epilepticus30 minutes of continuous
    seizures or five
  • minutes of convulsive seizures.
  • Lorazepam is drug of choice midazolam or
    propofol

PG 88
6
Anticonvulsant Drugs
  • AED monotherapy is preferred, but some patients
    do require combination therapy.
  • First-line AEDs for partial seizures include
    carbamazepine, phenytoin, lamotrigine, valproic
    acid, and oxcarbazepine.
  • First-line AEDs for generalized absence seizures
    include valproic acid and ethosuximide.
  • First-line AEDs for tonic-clonic seizures include
    phenytoin, carbamazepine, and valproic acid.
  • Alternative AEDs include gabapentin, topiramate,
    levetiracetam, zonisamide, tiagabine, primidone,
    felbamate, lamotrigine, and phenobarbital.

PG 89-90
7
PG 89-90
8
PG 89-90
9
  • Which of the following medications is NOT
    an inducer of the liver CYP450 system?
  • a. carbamazepine
  • b. phenytoin
  • c. valproate
  • d. olanzapine
  • e. phenobarbital

10
  • Which of the following medications is NOT
    an inducer of the liver CYP450 system?
  • a. carbamazepine
  • b. phenytoin
  • c. valproate
  • d. olanzapine
  • e. phenobarbital

11
  • Valproic acid is available in which of the
    following dosage forms?
  • I. Capsules
  • II. Liquid
  • III. Tablets
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, and III

12
  • Valproic acid is available in which of the
    following dosage forms?
  • I. Capsules
  • II. Liquid
  • III. Tablets
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, and III

13
  • A drug specific for petit mal is
  • a. clonazepam
  • b. diazepam
  • c. flurazepam
  • d. lorazepam
  • e. oxazepam

14
  • A drug specific for petit mal is
  • a. clonazepam
  • b. diazepam
  • c. flurazepam
  • d. lorazepam
  • e. oxazepam

15
  • Which of the following has no known drug
    interaction with oral contraceptives?
  • a. Neurontin
  • b. Carbamazepine
  • c. Valproic Acid
  • d. Phenytoin
  • e. Topiramate

16
  • Which of the following has no known drug
    interaction with oral contraceptives?
  • a. Neurontin
  • b. Carbamazepine
  • c. Valproic Acid
  • d. Phenytoin
  • e. Topiramate

17
Drugs to Treat Parkinsons Disease
NAPLEX
18
  • Drugs to Treat Parkinson Disease
  • Causes of Parkinson disease
  • Disruption of dopaminergic / cholinergic balance
  • Characteristics of patients (TRAP)
  • Slow onset Tremor, Rigidity, Akinesia, Postural
    instability
  • Drug therapy
  • Goals Mainly palliative attempt to inhibit
    cholinergic and attenuate dopaminergic action

PG 91
19
  • Drugs to Treat Parkinson Disease (contd)
  • Anticholinergic Drugs. Watch for dry mouth,
    constipation, urinary retention, intraoccular
    pressure
  • Procyclidine (Kemadrin)
  • Trihexyphenidyl (Artane)
  • Benztropine (Cogentin)
  • Biperiden (Akineton)
  • Diphenhydramine (Benadryl)

PG 91
20
  • Bradykinesia is best defined as
  • a. slow movements
  • b. rapid heart rate
  • c. narrowing of the pupil
  • d. excessive sweating
  • e. loss of desire for pleasurable
  • activities

21
  • Bradykinesia is best defined as
  • a. slow movements
  • b. rapid heart rate (tachycardia)
  • c. narrowing of the pupil (miosis)
  • d. excessive sweating (diaphoresis)
  • e. loss of desire for pleasurable
  • activities (apathy)

22
  • Drugs to Treat Parkinson Disease (contd)
  • Dopaminergic Agents
  • Levodopa (Larodopa, Dopar) - watch for on-off
    effect and B6 decreases efficacy, iron increases
    absorption
  • Levodopa/carbidopa (Sinemet) - wait 8 hours if
    converting from
  • levodopa. Cut levodopa dose to 25 of
    original.
  • Amantadine (Symmetrel) - increases release of
    dopamine stores (hypersensitivity) antiviral
    properties - antiviral for flu
  • Ergot-derived dopamine receptor agonists -
    stimulate dopamine
  • receptors (a) bromocriptine mesylate
    (Parlodel), and (b)
  • pergolide mesylate (Permax)

PG 91
23
  • Drugs to Treat Parkinson Disease (contd)
  • Nonergot dopamine receptor agonists -
    stimulate dopamine
  • receptors (a) pramipexole (Mirapex), (b)
    ropinirole (Requip), and
  • (c) rotigotine (Neupro Transdermal)
  • --- ropinirole approved to Restless Leg Syndrome
  • COMT inhibitors - adjunct that extends the
    action of
  • levodopa/carbidopa (a) Tolcapone (Tasmar),
    monitor hepatic
  • function, and (b) entacapone (Comtan)
  • ---no monotherapy
  • MAO-B inhibitor-adjunct that decreases
    breakdown of dopamine (a) selegiline (Eldepryl,
    Emsam, Zelapar), (b) rasagiline (Azilect)
  • ---watch for MAO-inhibitor drug interactions

PG 92
24
  • What information should the doctor know prior to
    initiating Mirapex in a patient with Parkinsons
    Disease?
  • I. Decrease the levodopa dose by 20-30 when
    initiating Mirapex
  • II. Patient must wear patch for 24 hours for
    efficacy
  • III. Monitor for serious cardiac side effects
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, III

25
  • What information should the doctor know prior to
    initiating Mirapex in a patient with Parkinsons
    Disease?
  • I. Decrease the levodopa dose by 20-30 when
    initiating Mirapex
  • II. Patient must wear patch for 24 hours for
    efficacy
  • III. Monitor for serious cardiac side effects
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, III

26
Alzheimer's Drugs
NAPLEX
p. 118
27
  • Drugs for Alzheimers Disease
  • Cholinesterase inhibitors all enhance
    cholinergic activity
  • Donepezil (Aricept)
  • Galantamine (Razadyne) (Reminyl D/C))
  • Rivastigmine (Exelon)
  • Glutamate antagonists
  • Memantine (Namenda)
  • Miscellaneous agents
  • Vitamin E
  • Selegiline (Eldepryl)

p. 118
28
Cholinesterase Inhibitors Dosing
  • Dose dependent side effects require titration
  • Start low and take in steps to avoid side effects

p. 118
29
  • Drugs for Alzheimers Disease
  • Adverse Effects
  • Cholinesterase inhibitors
  • Hepatotoxicity
  • Cholinergic effects (N/D, anorexia,
    salivation)
  • Bradycardia
  • Headache
  • Glutamate antagonists
  • Hypertension
  • Tachycardia
  • Insomnia

p. 118
30
Reference Sources for Pharmacists
NAPLEX
PG 399
PG
31
Literature Review
  • Primary literature ? Original journal articles
    (research reports, case reports, editorials)
    serves as information for development of
    secondary and tertiary literature resources
  • Secondary literature ? Indexing and abstracting
    services (e.g. MEDLINE, IPA, EMBASE, Cochrane)
  • Tertiary literature ? Textbooks and review
    articles summarize and interpret primary
    literature

PG 399
32
References
  • USP-NF
  • Official monographs for drug structure,
    solubilities, assays and therapeutic category
  • Limited info on dosage, dosage forms
  • USP DI (Micromedex)
  • Three volume set
  • I---DI for healthcare professionals (package
    insert) 11,000 drug products
  • II---Advice for patients easy to understand
  • III---Approved Drug products, legal requirements,
    Orange book
  • FDA Orange Book (electronic - 2004)
  • Bioequivalence information

PG 399
33
References
  • Remingtons
  • Pharmacy encyclopedia pharmacology,
    theoretical science, sterilization, practical
    pharmacy practice
  • Facts and Comparisons
  • Rx and OTC by therapeutic category monthly
    updates
  • AHFS
  • Good info on drug pharmacology intended for
    institutional
  • Blue Book / Red Book
  • Drugs / OTC / Cosmetics
  • Prices, NDC numbers, manufacturer address

PG 399
34
References
  • Physicians Desk Reference (PDR)
  • White pagesmanufacturer index of products
  • Pink pagesproduct names by trade name
  • Blue pagesproducts by therapeutic category
  • Yellow pagesgeneric and trade names with colored
    product ID
  • Martindales
  • Comprehensive drug lists (think foreign products
    - EUP)
  • Merck Manual
  • Describes diseases by symptoms
  • Merck Index
  • Listing of chemicals
  • Drugs in Pregnancy and Lactation (Briggs)
  • Gold standard

PG 399
35
  • A comparison of the relative daily cost of
    six brands of HCTZ can most easily be obtained by
    using the
  • a. Martindales Extra Pharmacopeia b. Facts
    and Comparisons
  • c. Red Book/Blue Book
  • d. Merck Index
  • e. Remingtons

36
  • A comparison of the relative daily cost of
    six brands of HCTZ can most easily be obtained by
    using the
  • a. Martindales Extra Pharmacopeia (drug lists
    foreign)
  • b. Facts and Comparisons (therapuetics)
  • c. Red Book/Blue Book (prices NDCs)
  • d. Merck Index (list of chemicals)
  • e. Remingtons (pharmacology)

37
  • Which of the following items is NOT presented in
    USP DI Volume III
  • a. Description of therapeutic uses for drugs
  • b. List of orphan drugs
  • c. Description of good pharmacy compounding
    practices
  • d. Definition of official storage conditions
  • e. The Federal Controlled Substances Act

38
  • Which of the following items is NOT presented in
    USP DI Volume III
  • a. Description of therapeutic uses for drugs
  • b. List of orphan drugs (Martidale)
  • c. Description of good pharmacy
    compounding practices (a handbook on

    compounding)
  • d. Definition of official storage conditions
  • (Remington's or AHFS)
  • e. The Federal Controlled Substances Act
    (Guide to Federal
    Pharmacy Law)

39
  • Compilation of information concerning parenteral
    drug solutions are found in
  • a. Goodman and Gilman
  • b. Martindales
  • c. Merck Index
  • d. Remingtons
  • e. Trissels

40
  • Compilation of information concerning parenteral
    drug solutions are found in
  • a. Goodman and Gilman
  • b. Martindales
  • c. Merck Index
  • d. Remingtons
  • e. Trissels

41
  • Solubility data for potassium gluconate will be
    found in
  • I. Merck Index
  • II. USP-NF
  • III. Remingtons
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, and III

42
  • Solubility data for potassium gluconate will be
    found in
  • I. Merck Index
  • II. USP-NF
  • III. Remingtons
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, and III

43
  • Contraindications for a commercial prescription
    drug may be located in
  • I. PDR
  • II. Merck Manual
  • III. USP-NF
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, and III

44
  • Contraindications for a commercial prescription
    drug may be located in
  • I. PDR
  • II. Merck Manual
  • III. USP-NF
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, and III

45
PG.40
46
  • What is the generic name for Actos?
  • a. Indinavir
  • b. Glyburide
  • c. Pioglitazone
  • d. Rosiglitazone
  • e. Zafirlukast

47
  • The pharmacist should inform the patient that the
    Actos
  • a. must be taken first thing in the morning
    before breakfast
  • b. must be taken with the evening meal
  • c. must be taken approximately 1 h before
    bedtime
  • d. requires consumption of at least 1 glass of
    water
  • e. may be taken any time during the day

48
  • The pharmacist should inform the patient that the
    Actos
  • a. must be taken first thing in the morning
    before breakfast
  • b. must be taken with the evening meal
  • c. must be taken approximately 1 h before
    bedtime
  • d. requires consumption of at least 1 glass of
    water
  • e. may be taken any time during the day

49
  • Which of the following cold remedies would be
    suitable for Ms Doolittles cough?
  • I. Robitussin DM
  • II. Robitussin AC
  • III. Robitussin PE
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, and III

50
  • Which of the following cold remedies would be
    suitable for Ms Doolittles cough?
  • I. Robitussin DM
  • II. Robitussin AC
  • III. Robitussin PE
  • a. I only
  • b. III only
  • c. I and II only
  • d. II and III only
  • e. I, II, and III

51
  • Which one of the following analgesics is most
    suitable to relieve the fever and headache of Ms.
    Doolittles 3-year-old boy?
  • a. Anacin
  • b. Ascriptin
  • c. Bayer PM
  • d. Panadol
  • e. Bayer Childrens Aspirin

52
  • Which one of the following analgesics is most
    suitable to relieve the fever and headache of Ms.
    Doolittles 3-year-old boy?
  • a. Anacin
  • b. Ascriptin
  • c. Bayer PM
  • d. Panadol (acetaminophen)
  • e. Bayer Childrens Aspirin
  • Reye Syndrome 1970s caused by inborn error of
    metabolism or toxin peak onset age 6,

53
  • Which one of the following drug products has the
    same active ingredient as Calan?
  • a. Dyazide
  • b. Effexor
  • c. Isordil
  • d. Plendil
  • e. Verelan

54
  • Which one of the following drug products has the
    same active ingredient as Calan?
  • a. Dyazide
  • b. Effexor
  • c. Isordil
  • d. Plendil
  • e. Verelan

55
(No Transcript)
56
  • Bactrim DS is probably being used to treat which
    of the following microorganisms?
  • Chlamydia pneumoniae
  • Clostridium difficile
  • Enterococcus faecalis
  • Escherichia coli
  • Pseudomonas aeruginosa

57
  • Bactrim DS is probably being used to treat which
    of the following microorganisms?
  • Chlamydia pneumoniae
  • Clostridium difficile
  • Enterococcus faecalis
  • Escherichia coli
  • Pseudomonas aeruginosa

58
  • Which of the following lab alterations would you
    expect to see in Ms. Brown as a result of
    starting the Bactrim DS?
  • Increased INR
  • Decreased INR
  • Increased potassium
  • Decreased potassium
  • Increased sodium

59
  • Which of the following lab alterations would you
    expect to see in Ms. Brown as a result of
    starting the Bactrim DS?
  • Increased INR
  • Decreased INR
  • Increased potassium
  • Decreased potassium
  • Increased sodium

60
  • A patient recently moved to the United States
    from England. She brings in her prescription
    bottle and asks the pharmacist if they carry the
    antibiotic that she has been taking for a UTI.
    Which of the following references could be used
    by the pharmacist to determine if there is an
    equivalent antibiotic available in the United
    States?
  • Facts and Comparisons
  • Martindale
  • Merck Index
  • PDR
  • Red Book

61
  • A patient recently moved to the United States
    from England. She brings in her prescription
    bottle and asks the pharmacist if they carry the
    antibiotic that she has been taking for a UTI.
    Which of the following references could be used
    by the pharmacist to determine if there is an
    equivalent antibiotic available in the United
    States?
  • Facts and Comparisons
  • Martindale
  • Merck Index
  • PDR
  • Red Book

62
THANKS!!!!!
Write a Comment
User Comments (0)
About PowerShow.com